

JUNE 2018

RESEARCH REPORT



ANTIBIOTIC RESISTANCE MARKETS - THERAPEUTICS.
By Pathogen and Therapy Type. With Situation Analysis,
Executive & Investor Guides & Customization
2018 to 2023





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the X-Ray market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- i. Antimicrobial Resistance - Strategic Situation Analysis..... 18
- ii. Guide for Executives, Marketing, Sales and Business Development Staff 20
- iii. Guide for Management Consultants and Investment Advisors..... 21
- 1. Introduction and Market Definition 22
 - 1.1 The Growing Threat and Opportunity of Antimicrobial Resistance 23
 - 1.2 Defining the Opportunity..... 25
 - 1.2.1 Revenue Market Size..... 25
 - 1.3 Methods and Sources 26
 - 1.3.1 Authors..... 26
 - 1.3.2 Sources 26
 - 1.4 U.S. Antibiotic Markets - Perspective 27
 - 1.4.1 U.S. Outpatient Use of Antibiotics 27
 - 1.4.2 U.S. Pharmaceutical Spending..... 30
- 2. Overview of a Dynamic Market..... 32
 - 2.1 Market Players – Roles & Impacts 33
 - 2.1.1 Drug manufacturers - Larger/pharmaceutical 33
 - 2.1.2 Drug manufacturers - Generic..... 34
 - 2.1.3 Contract Research and Manufacturing 35
 - 2.1.4 In Vitro Diagnostics Industry 35
 - 2.1.5 Drug Marketing Companies 36
 - 2.1.6 Biotechnology Companies..... 36

2.1.7 Regulatory Bodies 37

2.2 Understanding Antimicrobial Resistance..... 39

 2.2.1 What is Antimicrobial Resistance (AMR)..... 39

 2.2.2 Bacteria and Other Microbes 40

 2.2.3 The History of Antibiotics 44

 2.2.4 The Role of Animal Husbandry 48

 2.2.5 The Implications of Horizontal Transfer 49

 2.2.6 The Threat of AMR 50

2.3 The Changing Road to New Antibiotics & Technologies 52

2.4 The Key Role of Diagnostics in AMR 54

3. The Market Opportunity of AMR..... 55

 3.1 The Key Large Market Opportunities in AMR 56

 3.1.1 Streptococcus Pneumoniae (DRSP)..... 57

 3.1.2 Campylobacter (DRC) 59

 3.1.3 Clostridium Difficile (CD) 61

 3.1.4 Staphylococcus aureus (MRSA) 63

 3.1.5 Neisseria gonorrhoeae (DRNG) 65

 3.1.6 Salmonella (DRNTS)..... 67

 3.2 Therapeutic Technology Development Opportunities 69

 3.2.1 Using Viruses Against Bacteria 70

 3.2.2 Hydrolytic Enzymes Join the Fight..... 71

 3.2.3 Antibodies. 72

 3.2.4 Vaccines..... 74

 3.2.5 Probiotic Technology..... 75

3.2.6 Peptides vs. Pathogens..... 75

3.2.7 Mining Obsolete Science 76

3.2.8 CRISPR Antibiotics 76

3.3. Antibiotic Resistance Recent Developments 77

3.3.1 Recent Developments – Importance and How to Use This Section..... 77

3.3.2 Importance of These Developments 77

3.3.3 How to Use This Section..... 77

3.3.72 Amicrobe, Inc., patents AMR Gel 77

3.3.73 MICRONEEDLE PATCH TO COMBAT ANTIMICROBIAL RESISTANCE 78

3.3.74 Antimicrobial peptides find application medium..... 79

3.3.75 Antibiotic shortages fuelling antimicrobial resistance 79

3.3.4 Superbug Arises in China 80

3.3.5 Bruker Announces Acquisition of MERLIN 82

3.3.6 Antibiotics Firms Cemptra, Melinta Therapeutics Agree to Merger 83

3.3.7 Antibiotic Alternative Microeos wins Most Impactful Innovation 84

3.3.8 Roche kicks antibiotic development into Warp Drive..... 85

3.3.9 Iterum Gains Support for Sulopenem Development 86

3.3.10 VenatoRx Pharmaceuticals Raises \$42 Million Series B 87

3.3.11 Wockhardt Receives Approval for Phase III Trial 88

3.3.12 Phagelux, Inc. Announces Collaboration with Johnson & Johnson..... 90

3.3.13 bioMérieux, Inc. and McKesson Medical-Surgical Announce Distribution Alliance 90

3.3.14 AstraZeneca to sell antibiotics branch to Pfizer 91

3.3.15 Microbiotix and AMR Centre Announce Co-Development Agreement 92

3.3.16 Hennepin Life Sciences Presents Pre-Clinical Data 93

3.3.17 bioMérieux receives FDA clearance for expanded pathogen identification capability 94

3.3.18 Sequoia Sciences Receives FDA Fast Track Designation 95

3.3.19 Forge Therapeutics Presents New Efficacy Data 97

3.3.20 Acquisition Strategy Fills Out Roche's Pipeline 98

3.3.21 Alopexx completes trial of broad-spectrum anti-microbial vaccine 99

3.3.22 Integrated Biotherapeutics Partners with CARB-X for MRSA Vaccine 100

3.3.23 BD Molecular Test for Infectious Diarrhea Cleared 101

3.3.24 Fusion Genomics Developing All Pathogens Diagnostic..... 102

4. Key Biotechnology Companies and Their Technology..... 104

4.2 Therapeutics 104

4.2.1 The Medicines Company 105

4.2.2 Melinta Therapeutics 106

4.2.3 Arsanis 107

4.2.4 Phage Technologies S.A..... 108

4.2.5 Westway Health 109

4.2.6 Tetrphase Pharmaceuticals 110

4.2.7 BioVersys GmbH..... 111

4.2.8 Nabriva Therapeutics. 112

4.2.9 Macrolide Pharmaceuticals 113

4.2.10 Nemesis Bioscience 114

4.2.11 C3J Therapeutics, Inc..... 115

4.2.12 EpiBiome 116

4.2.13 discuva 117

4.2.14 SmartPhage 119

4.2.15 AmpliPhi Biosciences 120

4.2.16 Pherecydes Pharma..... 121

4.2.17 Microeos..... 122

4.2.18 Procarta Biosystems 123

4.2.19 Lumavita 125

4.2.20 Madam Therapeutics 126

4.2.21 Priaxon 127

4.2.22 Biolytx Pharmaceuticals 128

4.2.23 AntibioTx 129

4.2.24 Xellia Pharmaceuticals..... 130

4.2.25 Paratek Pharmaceuticals 131

4.2.26 Synereca Pharmaceuticals..... 132

4.2.27 Allecra Therapeutics..... 133

4.2.28 Fixed Phage 134

4.2.29 Enanta Pharmaceuticals, Inc. 135

4.2.30 Demuris 136

4.2.31 Prommune..... 137

4.2.32 Biosergen..... 138

4.2.33 Innovation Pharmaceuticals..... 139

4.2.34 Aviragen Therapeutics..... 140

4.2.35 Achillion Pharmaceuticals 141

4.2.36 ImmunNovative Developments, S.L. 142

4.2.37 Achaogen, Inc. 143

4.2.38 SelectX Pharmaceuticals, Inc. 144

4.2.39 TaiGen Biotechnology Co., Ltd.	145
4.2.40 Theravance Biopharma	146
4.2.41 Abbvie	148
4.2.42 KYORIN Pharmaceutical Co.,Ltd.....	150
4.2.43 Iterum Therapeutics Limited.....	151
4.2.44 Forge Therapeutics.....	152
4.2.45 Alopexx Vaccine LLC	153
4.2.46 Integrated Biotherapeutics	154
4.2.47 Hennepin Life Sciences.....	155
4.2.48 Fedora Pharmaceuticals Inc.	156
4.2.49 Contrafect Corporation	157
4.2.50 Basilea Pharmaceutica Ltd.	158
4.2.51 AiCuris	160
4.2.52 RedHill Biopharma.....	161
4.2.53 Redx Pharma Plc/ Redx Anti Infectives Ltd.	163
4.2.54 ABAC Therapeutics	164
4.2.55 Alaxia SAS	165
4.2.56 Antabio S.A.S.....	166
4.2.57 Auspherix Ltd.....	167
4.2.58 BioFilm Pharma	168
4.2.59 Centauri Therapeutics Ltd	169
4.2.60 Combioxin SA	170
4.2.61 Da Volterra	171
4.2.62 Debiopharm International SA.....	172

4.2.63 Deinobiotics/Deinove.....	173
4.2.64 Destiny Pharma plc.....	174
4.2.65 Eligo Bioscience	175
4.2.66 Helperby Therapeutics Ltd	176
4.2.67 Karveel Pharmaceuticals	177
4.2.68 MaaT Pharma	178
4.2.69 Motif BioSciences, Inc / Motif Bio PLC	179
4.2.70 Mutabilis SAS.....	181
4.2.71 Neem Biotech Ltd.....	183
4.2.72 Northern Antibiotics Oy (Ltd).....	184
4.2.73 Nosopharm.....	185
4.2.74 NovaBiotics Ltd.....	186
4.2.75 Phico Therapeutics Ltd	187
4.2.76 Polyphor Ltd	189
4.2.77 QureTech Bio AB	190
4.2.78 SetLance srl.....	191
4.2.79 Ultupharma AB	192
4.2.80 Vaxdyn.....	193
4.2.81 Vibiosphen	194
4.2.82 Bioaster	195
4.2.83 Vivexia	196
4.2.85 KBP Biosciences	197
4.2.86 Absynth Biologics	198
4.2.87 Spero Therapeutics	199

4.2.88 Merck	200
4.2.89 Symphogen.....	202
4.2.90 Warp Drive Bio	203
4.2.91 Johnson & Johnson (Janssen)	205
4.2.92 Pfizer	207
4.2.93 Allergan	209
4.2.95 Novartis.....	211
4.2.97 AstraZeneca	214
4.2.100 Cipla.....	218
4.2.101 DSM Sinochem Pharmaceuticals.....	219
4.2.102 Wockhardt Ltd.....	220
4.2.103 VenatoRx Pharmaceuticals.....	221
4.2.104 MicuRx	223
4.2.105 Entasis Therapeutics.....	224
4.2.106 Merlion Pharmaceuticals.....	225
4.2.107 Aridis Pharmaceuticals Inc	226
4.3 The Therapeutics Race – Summary of Companies Research Areas	227
5. Country Market Sizes – North America 2017 to 2023	228
5.1 United States of America 2017 to 2023.....	229
5.1.1 USA by Pathogen.....	229
5.1.2 USA by Technology Opportunity	230
5.2 Canada 2017 to 2023	231
5.1.1 Canada by Pathogen.....	231
5.1.2 Canada by Technology Opportunity.....	232

6. Country Markets – Europe 2017 to 2023	233
6.1 France 2017 to 2023	234
6.1.1 France by Pathogen.....	234
6.1.2 France by Technology Opportunity.....	235
6.2 Germany 2017 to 2023	236
6.2.1 Germany by Pathogen.....	236
6.2.2 Germany by Technology Opportunity.....	237
6.3 United Kingdom 2017 to 2023	238
6.3.1 United Kingdom by Pathogen	238
6.3.2 United Kingdom by Technology Opportunity	239
6.4 Spain 2017 to 2023	240
6.4.1 Spain by Pathogen.....	240
6.4.2 Spain by Technology Opportunity.....	241
6.5 Italy 2017 to 2023	242
6.5.1 Italy by Pathogen.....	242
6.5.2 Italy by Technology Opportunity.....	243
6.6 Russia 2017 to 2023	244
6.6.1 Russia by Pathogen	244
6.6.2 Russia by Technology Opportunity	245
6.7 Remainder of Europe and Former USSR 2017 to 2023.....	246
6.7.1 Remainder of Europe and Former USSR by Pathogen	246
6.7.2 Remainder of Europe and Former USSR by Technology Opportunity	247
7. Country Markets – Asia Pacific 2017 to 2023.....	248
7.1 China 2017 to 2023	249

7.1.1 China by Pathogen	249
7.1.2 China by Technology Opportunity.....	250
7.2 Japan 2017 to 2023.....	251
7.2.1 Japan by Pathogen	251
7.2.2 Japan by Technology Opportunity	252
7.3 South Korea 2017 to 2023	253
7.3.1 South Korea by Pathogen.....	253
7.3.2 South Korea by Technology Opportunity.....	254
7.4 India 2017 to 2023	255
7.4.1 India by Pathogen.....	255
7.4.2 India by Technology Opportunity.....	256
7.5 Australia 2017 to 2023.....	257
7.5.1 Australia by Pathogen	257
7.5.2 Australia by Technology Opportunity	258
7.6 Remainder of Asia Pacific 2017 to 2023	259
7.6.1 Remainder of Asia Pacific by Pathogen.....	259
7.6.2 Remainder of Asia Pacific by Technology Opportunity.....	260
8. Country Markets – Latin America, Africa & The Middle East 2017 to 2023.....	261
8.1 Brazil 2017 to 2023	262
8.1.1 Brazil by Pathogen.....	262
8.1.2 Brazil by Technology Opportunity.....	263
8.2 Mexico 2017 to 2023	264
8.2.1 Mexico by Pathogen.....	264
8.2.2 Mexico by Technology Opportunity.....	265

8.3 Remainder of Latin America 2017 to 2023	266
8.3.1 Remainder of Latin America by Pathogen.....	266
8.3.2 Remainder of Latin America by Technology Opportunity.....	267
8.4 Africa & The Middle East 2017 to 2023	268
8.4.1 Africa & The Middle East by Pathogen.....	268
8.4.2 Africa & The Middle East by Technology Opportunity.....	269
9. Global Market Summary 2017 to 2023	270
9.1 Global Market Summary 2017 to 2023.....	271
9.1.1 Global Market Summary by Pathogen	271
9.1.2 Global Market Summary by Technology Opportunity	272
10. The Future of AMR	273
Appendices	274
I. United States Medicare System: Top Selling Drugs 2011-2015.....	274

Table of Tables

Table 1 USA - Outpatient Use of Antibiotics by Class.....	28
Table 2 USA - Outpatient Use of Antibiotics Top 5.....	29
Table 3 Market Players by Type.....	33
Table 4 Known Human Pathogenic Diseases.....	42
Table 5 The Key Market Opportunities	56
Table 6 - Market Potential DRSP Therapeutic.....	58

Table 7 - Market Potential DRC Therapeutic..... 60

Table 8 Eight Technologies under development 69

Table 9 Antibodies Approved for Infectious Disease Treatment 72

Table 10 Therapeutic Technology Research - # of Companies..... 227

Table 11 USA by Pathogen..... 229

Table 12 USA by Technology Opportunity..... 230

Table 13 Canada by Pathogen 231

Table 14 Canada by Technology Opportunity 232

Table 15 France By Pathogen 234

Table 16 France By Technology Opportunity 235

Table 17 Germany By Pathogen 236

Table 18 Germany By Technology Opportunity 237

Table 19 UK By Pathogen..... 238

Table 20 UK By Technology Opportunity..... 239

Table 21 Spain by Pathogen 240

Table 22 Spain by Technology Opportunity 241

Table 23 Italy By Pathogen 242

Table 24 Italy By Technology Opportunity 243

Table 25 Russia By Pathogen 244

Table 26 Russia By Technology Opportunity 245

Table 27 Remainder of Europe and Former USSR By Pathogen..... 246

Table 28 Remainder of Europe and Former USSR By Technology Opportunity..... 247

Table 29 China By Pathogen 249

Table 30 China By Technology Opportunity 250

Table 31 Japan By Pathogen	251
Table 32 Japan By Technology Opportunity	252
Table 33 South Korea By Pathogen	253
Table 34 South Korea By Technology Opportunity	254
Table 35 India by Pathogen	255
Table 36 India by Technology Opportunity	256
Table 37 Australia By Pathogen.....	257
Table 38 Australia By Technology Opportunity.....	258
Table 39 Remainder of Asia Pacific By Pathogen	259
Table 40 Remainder of Asia Pacific By Technology Opportunity	260
Table 41 Brazil By Pathogen	262
Table 42 Brazil By Technology Opportunity	263
Table 43 Mexico By Pathogen	264
Table 44 Mexico By Technology Opportunity	265
Table 45 Remainder of Latin America By Pathogen	266
Table 46 Remainder of Latin America By Technology Opportunity	267
Table 47 Africa & The Middle East by Pathogen	268
Table 48 Africa & The Middle East by Technology Opportunity	269
Table 49 Global Market Summary by Pathogen.....	271
Table 50 Global Market Summary by Technology Opportunity.....	272
Table 51 2011 to 2015 Top Selling Drugs	274

Table of Figures

Figure 1 Pharmaceutical Spending History by Country 30

Figure 2 AMR and Antibiotic Introduction 47

Figure 3 The Death Toll of AMR..... 51

Figure 4 Phage T4 Anatomy and Infection Cycle..... 70